Using Nitazoxanide to prevent recurrence of hepatic encephalopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of Nitazoxanide in preventing the recurrence of hepatic encephalopathy in cirrhotic patients. The study involves administering Nitazoxanide alongside Rifaximin to assess its effectiveness in reducing the frequency of episodes in patients who have previously experienced hepatic encephalopathy. Participants will be monitored for safety and efficacy throughout the trial period. The study aims to provide a potential new treatment option for managing this serious condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cirrhotic patient with at least one previous episode of hepatic encephalopathy.
* Adult Patients aging from 20 to 65 years old

Exclusion Criteria:

* Active GIT bleeding.
* Major psychiatric illness (psychosis \& epilepsy).
* Renal insufficiency (S.Cr 2mg/dl).

Where it's running

• Sherief Abd-Elsalam
  Tanta, Egypt Recruiting

Study contacts

• Principal investigator: Khadija Ahmed Glal, Msc — Tanta University
• Study coordinator: Sherief Abd-Elsalam, ass. prof.
• Email: sheriefabdelsalam@yahoo.com
• Phone: 00201147773440

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Coil-assisted small-diameter stent shunt reduction for refractory HE after TIPS

  A coil-assisted, small-diameter covered-stent technique is being tested to see if it can safely and effectively reduce shunt flow and lessen recurrent hepatic encephalopathy in people with a prior TIPS.

  Recruiting Air Force Military Medical University, China · Xi'an, Shaanxi · NCT07799948

• Fecal transplant plus standard therapy for refractory hepatic encephalopathy after TIPS

  This study tests whether adding fecal microbiota transplantation to usual medicines helps people with recurrent hepatic encephalopathy after TIPS implant.

  Recruiting Early Phase 1 Air Force Military Medical University, China · Xi'an · NCT07683936

• Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis

  This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.

  Recruiting Phase 4 Asian Institute Of Medical Sciences · Hyderābād, Sindh · NCT07521332

• Developing and testing the Liver Cirrhosis Cognitive Decline Scale (LiCCoS)

  This project will test a short questionnaire called LiCCoS to see if it can spot thinking and everyday mental problems in adults with liver cirrhosis.

  Recruiting University of Malaya · Ambāla, Haryana · NCT07418008

• Melatonin to improve sleep and thinking in people with cirrhosis

  This study will try one month of daily melatonin (compared with one month of thiamine) to see if it improves sleep and thinking in adults with cirrhosis and hepatic encephalopathy.

  Recruiting Weill Medical College of Cornell University · New York, New York · NCT07046429

• Examining the link between serum albumin levels and hepatic encephalopathy severity in chronic liver disease patients

  This study is trying to see if the level of a protein called serum albumin in the blood is related to how severe brain problems are in people with chronic liver disease.

  Recruiting Sohag University · Sohag · NCT06953921

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.